Evidence map›Paper›PMID 41003926›Full record

ArticleEJNMMI research2025

Tumor sink effect on melanin-ligand [

Elodie Jouberton, Sophie Besse, Tommy Billoux, Philippe Auzeloux, Sébastien Schmitt, Jean-Michel Chezal, Nicolas Sas, Laurine Noirault, Manon Auriol, Sophie Levesque and 6 more

Abstract read
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elodie JoubertonService de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France. elodie.jouberton@clermont.unicancer.fr.ORCID http://orcid.org/0000-0002-0275-4055
Sophie BesseImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Tommy BillouxImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Philippe AuzelouxImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Sébastien SchmittImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Jean-Michel ChezalImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Nicolas SasImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Laurine NoiraultImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Manon AuriolImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Sophie LevesqueService de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.
Marine DelmasService de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.
Benjamin ChaussinImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Emmanuel ChautardImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Elisabeth Miot-NoiraultImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Jacques RouanetImagerie Moléculaire Et Stratégies Théranostiques, Université Clermont Auvergne, INSERM UMR1240, Clermont-Ferrand, France.
Florent CachinService de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe tumor sink effect refers to the sequestration of a radiopharmaceutical compound by tumors, leading to a reduced bioavailability in non-target organs and potential alterations in radiopharmaceuticals distribution. This phenomenon has been widely studied in neuroendocrine, thyroid, and prostate cancers but remains unexplored for melanin-targeting radiopharmaceuticals in metastatic melanoma. [

resultsWe conducted an ex vivo biodistribution study using syngeneic murine melanoma models (B16-F10, B16-OVA, B16BL6) and correlated tumor volume with radiopharmaceutical uptake. In models, γ-counting revealed significant tumor uptake (18.8 ± 4.5 IA%/g at 24 h after injection of [

conclusionThese findings suggest that tumor burden impacts [

Indexed as

[131I]ICF01012In vivoMurine melanoma modelsTargeted radionuclide therapyTumor sink effect

Identifiers

PMID41003926
PMCPMC12474777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.